Slot System
Featured Buckets
Featured Buckets Admin

New therapies for type 2 diabetes based on glucagon-like peptide 1

Article Type
Changed
Tue, 05/03/2022 - 16:09
Display Headline
New therapies for type 2 diabetes based on glucagon-like peptide 1
Article PDF
Author and Disclosure Information

Marzieh Salehi, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

David A. D’Alessio, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

Address: Marzieh Salehi, MD, Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, PO Box 670547, Cincinnati, OH 45267-0547; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(4)
Publications
Topics
Page Number
382-389
Sections
Author and Disclosure Information

Marzieh Salehi, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

David A. D’Alessio, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

Address: Marzieh Salehi, MD, Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, PO Box 670547, Cincinnati, OH 45267-0547; e-mail [email protected]

Author and Disclosure Information

Marzieh Salehi, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

David A. D’Alessio, MD
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH

Address: Marzieh Salehi, MD, Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, PO Box 670547, Cincinnati, OH 45267-0547; e-mail [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(4)
Issue
Cleveland Clinic Journal of Medicine - 73(4)
Page Number
382-389
Page Number
382-389
Publications
Publications
Topics
Article Type
Display Headline
New therapies for type 2 diabetes based on glucagon-like peptide 1
Display Headline
New therapies for type 2 diabetes based on glucagon-like peptide 1
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Side effects of antidepressants: An overview

Article Type
Changed
Mon, 07/23/2018 - 15:43
Display Headline
Side effects of antidepressants: An overview
Article PDF
Author and Disclosure Information

Elias A. Khawam, MD
Louis Stokes Cleveland VA Medical Center; Senior Instructor, Department of Psychiatry, Case Western Reserve University

Georgia Laurencic, MD
Department of Psychiatry and Psychology, Cleveland Clinic

Donald A. Malone Jr., MD
Head, Section of Adult Primary Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: Donald Malone, Jr., MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(4)
Publications
Topics
Page Number
351-353, 356-360-361
Sections
Author and Disclosure Information

Elias A. Khawam, MD
Louis Stokes Cleveland VA Medical Center; Senior Instructor, Department of Psychiatry, Case Western Reserve University

Georgia Laurencic, MD
Department of Psychiatry and Psychology, Cleveland Clinic

Donald A. Malone Jr., MD
Head, Section of Adult Primary Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: Donald Malone, Jr., MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Author and Disclosure Information

Elias A. Khawam, MD
Louis Stokes Cleveland VA Medical Center; Senior Instructor, Department of Psychiatry, Case Western Reserve University

Georgia Laurencic, MD
Department of Psychiatry and Psychology, Cleveland Clinic

Donald A. Malone Jr., MD
Head, Section of Adult Primary Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: Donald Malone, Jr., MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 73(4)
Issue
Cleveland Clinic Journal of Medicine - 73(4)
Page Number
351-353, 356-360-361
Page Number
351-353, 356-360-361
Publications
Publications
Topics
Article Type
Display Headline
Side effects of antidepressants: An overview
Display Headline
Side effects of antidepressants: An overview
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Aldosterone receptor antagonists for heart failure: Current status, future indications

Article Type
Changed
Mon, 07/23/2018 - 13:47
Display Headline
Aldosterone receptor antagonists for heart failure: Current status, future indications
Article PDF
Author and Disclosure Information

Bertram Pitt, MD
University of Michigan School of Medicine, Ann Arbor, MI; investigator in the RALES, EPHESUS, and 4E trials

Sanjay Rajagopalan, MD
Mt. Sinai School of Medicine, New York, NY

Address: Sanjay Rajagopalan, MD, One Gustave Levy Place, Box 1030, New York, NY 10029; e-mail [email protected]

Dr. Pitt has indicated that he serves as a consultant for the Pfizer corporation.

Issue
Cleveland Clinic Journal of Medicine - 73(3)
Publications
Topics
Page Number
257-260, 264-268
Sections
Author and Disclosure Information

Bertram Pitt, MD
University of Michigan School of Medicine, Ann Arbor, MI; investigator in the RALES, EPHESUS, and 4E trials

Sanjay Rajagopalan, MD
Mt. Sinai School of Medicine, New York, NY

Address: Sanjay Rajagopalan, MD, One Gustave Levy Place, Box 1030, New York, NY 10029; e-mail [email protected]

Dr. Pitt has indicated that he serves as a consultant for the Pfizer corporation.

Author and Disclosure Information

Bertram Pitt, MD
University of Michigan School of Medicine, Ann Arbor, MI; investigator in the RALES, EPHESUS, and 4E trials

Sanjay Rajagopalan, MD
Mt. Sinai School of Medicine, New York, NY

Address: Sanjay Rajagopalan, MD, One Gustave Levy Place, Box 1030, New York, NY 10029; e-mail [email protected]

Dr. Pitt has indicated that he serves as a consultant for the Pfizer corporation.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(3)
Issue
Cleveland Clinic Journal of Medicine - 73(3)
Page Number
257-260, 264-268
Page Number
257-260, 264-268
Publications
Publications
Topics
Article Type
Display Headline
Aldosterone receptor antagonists for heart failure: Current status, future indications
Display Headline
Aldosterone receptor antagonists for heart failure: Current status, future indications
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

What is a 'failure' of bisphosphonate therapy for osteoporosis?

Article Type
Changed
Wed, 09/12/2018 - 08:53
Display Headline
What is a 'failure' of bisphosphonate therapy for osteoporosis?
Article PDF
Author and Disclosure Information

John J. Carey, MD
Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: John J. Carey, MD, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Carey has indicated that he has received grant or research support from the Proctor and Gamble corporation, serves as a consultant for Eli Lilly and Company, and is on the speaker’s bureau of Proctor and Gamble.

Issue
Cleveland Clinic Journal of Medicine - 72(11)
Publications
Topics
Page Number
1033-1039
Sections
Author and Disclosure Information

John J. Carey, MD
Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: John J. Carey, MD, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Carey has indicated that he has received grant or research support from the Proctor and Gamble corporation, serves as a consultant for Eli Lilly and Company, and is on the speaker’s bureau of Proctor and Gamble.

Author and Disclosure Information

John J. Carey, MD
Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: John J. Carey, MD, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Carey has indicated that he has received grant or research support from the Proctor and Gamble corporation, serves as a consultant for Eli Lilly and Company, and is on the speaker’s bureau of Proctor and Gamble.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Page Number
1033-1039
Page Number
1033-1039
Publications
Publications
Topics
Article Type
Display Headline
What is a 'failure' of bisphosphonate therapy for osteoporosis?
Display Headline
What is a 'failure' of bisphosphonate therapy for osteoporosis?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Safety of statins: Effects on muscle and the liver

Article Type
Changed
Wed, 09/12/2018 - 08:39
Display Headline
Safety of statins: Effects on muscle and the liver
Article PDF
Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Issue
Cleveland Clinic Journal of Medicine - 72(11)
Publications
Topics
Page Number
990-993, 996-1001
Sections
Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Author and Disclosure Information

Abu R. Vasudevan, MBBS, MD, MRCP
Clinical Instructor, Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Yasmin S. Hamirani, MBBS
Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Peter H. Jones, MD
Associate Professor, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160, Mail stop A601, Houston, TX 77030; e-mail [email protected]

Dr. Jones has indicated that he has received grant or research support from the Abbott, AstraZeneca, KOS, and Pfizer corporations.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Page Number
990-993, 996-1001
Page Number
990-993, 996-1001
Publications
Publications
Topics
Article Type
Display Headline
Safety of statins: Effects on muscle and the liver
Display Headline
Safety of statins: Effects on muscle and the liver
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

DHEA supplementation: The claims in perspective

Article Type
Changed
Tue, 05/03/2022 - 16:09
Display Headline
DHEA supplementation: The claims in perspective
Article PDF
Author and Disclosure Information

Ewa Olech, MD
Clinical Pharmacology Research Program,Oklahoma Medical Research Foundation; Clinical Assistant Professor, University of Oklahoma Health Sciences Center, Oklahoma City

Joan T. Merrill, MD
Head, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, and Professor of Medicine, Oklahoma Health Sciences Center, Oklahoma City; Medical Director, Lupus Foundation of America

Address: Joan T. Merrill, MD, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104

Dr. Merrill has indicated that she is a consultant for Genelabs and has received grant or research support from Genelabs.

Issue
Cleveland Clinic Journal of Medicine - 72(11)
Publications
Topics
Page Number
965-966, 968, 970-971, 975-977, 983-984
Sections
Author and Disclosure Information

Ewa Olech, MD
Clinical Pharmacology Research Program,Oklahoma Medical Research Foundation; Clinical Assistant Professor, University of Oklahoma Health Sciences Center, Oklahoma City

Joan T. Merrill, MD
Head, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, and Professor of Medicine, Oklahoma Health Sciences Center, Oklahoma City; Medical Director, Lupus Foundation of America

Address: Joan T. Merrill, MD, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104

Dr. Merrill has indicated that she is a consultant for Genelabs and has received grant or research support from Genelabs.

Author and Disclosure Information

Ewa Olech, MD
Clinical Pharmacology Research Program,Oklahoma Medical Research Foundation; Clinical Assistant Professor, University of Oklahoma Health Sciences Center, Oklahoma City

Joan T. Merrill, MD
Head, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, and Professor of Medicine, Oklahoma Health Sciences Center, Oklahoma City; Medical Director, Lupus Foundation of America

Address: Joan T. Merrill, MD, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104

Dr. Merrill has indicated that she is a consultant for Genelabs and has received grant or research support from Genelabs.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Issue
Cleveland Clinic Journal of Medicine - 72(11)
Page Number
965-966, 968, 970-971, 975-977, 983-984
Page Number
965-966, 968, 970-971, 975-977, 983-984
Publications
Publications
Topics
Article Type
Display Headline
DHEA supplementation: The claims in perspective
Display Headline
DHEA supplementation: The claims in perspective
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Angiotensin-receptor blockers: Benefits beyond lowering blood pressure

Article Type
Changed
Tue, 09/11/2018 - 10:24
Display Headline
Angiotensin-receptor blockers: Benefits beyond lowering blood pressure
Article PDF
Author and Disclosure Information

Russell L. Silverstein, MD
Senior Physician and Vice President, Dallas Nephrology Associates, Dallas, TX

C. Venkata S. Ram, MD
Director, Texas Blood Pressure Institute, Dallas Nephrology Associates; University of Texas Southwestern Medical School, Dallas, TX

Address: C. Venkata S. Ram, MD, Director, Texas Blood Pressure Institute, 1420 Viceroy Drive, Dallas, TX 75235; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 72(9)
Publications
Topics
Page Number
825-832
Sections
Author and Disclosure Information

Russell L. Silverstein, MD
Senior Physician and Vice President, Dallas Nephrology Associates, Dallas, TX

C. Venkata S. Ram, MD
Director, Texas Blood Pressure Institute, Dallas Nephrology Associates; University of Texas Southwestern Medical School, Dallas, TX

Address: C. Venkata S. Ram, MD, Director, Texas Blood Pressure Institute, 1420 Viceroy Drive, Dallas, TX 75235; e-mail [email protected]

Author and Disclosure Information

Russell L. Silverstein, MD
Senior Physician and Vice President, Dallas Nephrology Associates, Dallas, TX

C. Venkata S. Ram, MD
Director, Texas Blood Pressure Institute, Dallas Nephrology Associates; University of Texas Southwestern Medical School, Dallas, TX

Address: C. Venkata S. Ram, MD, Director, Texas Blood Pressure Institute, 1420 Viceroy Drive, Dallas, TX 75235; e-mail [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(9)
Issue
Cleveland Clinic Journal of Medicine - 72(9)
Page Number
825-832
Page Number
825-832
Publications
Publications
Topics
Article Type
Display Headline
Angiotensin-receptor blockers: Benefits beyond lowering blood pressure
Display Headline
Angiotensin-receptor blockers: Benefits beyond lowering blood pressure
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Statins: The case for higher, individualized starting doses

Article Type
Changed
Tue, 09/11/2018 - 09:39
Display Headline
Statins: The case for higher, individualized starting doses
Article PDF
Author and Disclosure Information

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail [email protected]

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.

Issue
Cleveland Clinic Journal of Medicine - 72(9)
Publications
Topics
Page Number
811-816
Sections
Author and Disclosure Information

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail [email protected]

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.

Author and Disclosure Information

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail [email protected]

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 72(9)
Issue
Cleveland Clinic Journal of Medicine - 72(9)
Page Number
811-816
Page Number
811-816
Publications
Publications
Topics
Article Type
Display Headline
Statins: The case for higher, individualized starting doses
Display Headline
Statins: The case for higher, individualized starting doses
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Management of erectile dysfunction by the primary care physician

Article Type
Changed
Mon, 09/10/2018 - 08:04
Display Headline
Management of erectile dysfunction by the primary care physician
Article PDF
Author and Disclosure Information

Nasser Mikhail, MD, MSc
Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA

Address: Nasser Mikhail, MD, MSc, Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342-1495; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 72(4)
Publications
Topics
Page Number
293-294, 296-297, 301-305, 310-311
Sections
Author and Disclosure Information

Nasser Mikhail, MD, MSc
Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA

Address: Nasser Mikhail, MD, MSc, Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342-1495; e-mail [email protected]

Author and Disclosure Information

Nasser Mikhail, MD, MSc
Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA

Address: Nasser Mikhail, MD, MSc, Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342-1495; e-mail [email protected]

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 72(4)
Issue
Cleveland Clinic Journal of Medicine - 72(4)
Page Number
293-294, 296-297, 301-305, 310-311
Page Number
293-294, 296-297, 301-305, 310-311
Publications
Publications
Topics
Article Type
Display Headline
Management of erectile dysfunction by the primary care physician
Display Headline
Management of erectile dysfunction by the primary care physician
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis

Article Type
Changed
Thu, 11/15/2018 - 07:55
Display Headline
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
Article PDF
Author and Disclosure Information

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Issue
Cleveland Clinic Journal of Medicine - 70(7)
Publications
Topics
Page Number
585-586, 589-590, 592-594, 597-598, 600-601
Sections
Author and Disclosure Information

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Author and Disclosure Information

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 70(7)
Issue
Cleveland Clinic Journal of Medicine - 70(7)
Page Number
585-586, 589-590, 592-594, 597-598, 600-601
Page Number
585-586, 589-590, 592-594, 597-598, 600-601
Publications
Publications
Topics
Article Type
Display Headline
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
Display Headline
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media